Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune Inc is poised for a positive outlook due to the significant efficacy demonstrated by pemvidutide in reducing liver fat, as evidenced by the MASLD trial, which reported up to 76% liver fat reduction and prominent improvements in key biomarkers associated with hepatic inflammation and fibrosis progression. The favorable tolerability profile of pemvidutide compared to other therapies enhances its attractiveness in the treatment landscape for obesity and metabolic diseases, particularly as it targets conditions like alcoholic liver disease (ALD) and metabolic-associated steatohepatitis (MASH). Furthermore, the company's strategic focus on leveraging pemvidutide's unique dual mechanism of action alongside the FDA's openness to non-invasive endpoints highlights potential pathways for expedited regulatory approval, maintaining high expectations for upcoming trial results.
Bears say
Altimmune's outlook is negatively impacted by the significant clinical development risks associated with pemvidutide, particularly as it competes with existing therapies that have proven to be suboptimal in efficacy and tolerability, despite some patient weight loss successes. Additionally, the company faces challenges related to commercialization, pricing, and reimbursement, heightening the overall risk profile for potential market adoption. Furthermore, external factors such as ongoing global uncertainties, including COVID-19 and regional conflicts, add layers of complexity that could disrupt clinical trials and future prospects.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares